SSRI use and clinical outcomes in epithelial ovarian cancer

Desiré K. Christensen, Guillermo N. Armaiz-Pena, Edgardo Ramirez, Koji Matsuo, Bridget Zimmerman, Behrouz Zand, Eileen Shinn, Michael J. Goodheart, David Bender, Premal H. Thaker, Amina Ahmed, Frank J. Penedo, Koenraad De Geest, Luis Mendez, Frederick Domann, Anil K. Sood, Susan K. Lutgendorf

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Selective serotonin reuptake inhibitor (SSRI) use is common among ovarian cancer patients. We examined the effect of SSRIs on survival and progression in ovarian cancer patients and effects of 5-HT on ovarian cancer cell (OCC) proliferation. Ovarian cancer patients from a 6-site study between 1994 and 2010 were included. Cox proportional hazards models were used for multivariate analysis. SSRI use was associated with decreased time to disease recurrence (HR 1.3, CI 1.0-1.6, p=0.03), but not overall survival (HR 1.1, CI 0.9-1.3, p=0.56). Compared to normal ovarian cells, most OCCs had elevated 5-HT2A receptor mRNA expression (up to 1600 fold greater expression). Clonogenic survival increased in cells treated with 10 uM (1.6 fold, p

Original languageEnglish (US)
Pages (from-to)33179-33191
Number of pages13
JournalOncotarget
Volume7
Issue number22
DOIs
StatePublished - May 31 2016

    Fingerprint

Keywords

  • Cell proliferation
  • Epithelial ovarian cancer
  • Progression
  • Selective serotonin reuptake inhibitors
  • Serotonin

ASJC Scopus subject areas

  • Oncology

Cite this

Christensen, D. K., Armaiz-Pena, G. N., Ramirez, E., Matsuo, K., Zimmerman, B., Zand, B., Shinn, E., Goodheart, M. J., Bender, D., Thaker, P. H., Ahmed, A., Penedo, F. J., De Geest, K., Mendez, L., Domann, F., Sood, A. K., & Lutgendorf, S. K. (2016). SSRI use and clinical outcomes in epithelial ovarian cancer. Oncotarget, 7(22), 33179-33191. https://doi.org/10.18632/oncotarget.8891